Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
about
Combination approaches improve predictive performance of diagnostic rules for mass-spectrometry proteomic data.Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survival.Complexity in the genetic architecture of leukoaraiosis in hypertensive sibships from the GENOA StudyTo aggregate or not to aggregate high-dimensional classifiersImproved classification of breast cancer peptide and protein profiles by combining two serum workup proceduresProteomic serum biomarkers and their potential application in cancer screening programs.Detection of pancreatic cancer using serum protein profiling.Serum peptide signatures for pancreatic cancer based on mass spectrometry: a comparison to CA19-9 levels and routine imaging techniques.Application of a Serum Protein Signature for Pancreatic Cancer to Separate Cases from Controls in a Pancreatic Surveillance Cohort.Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension.Accuracy and Reproducibility in Quantification of Plasma Protein Concentrations by Mass Spectrometry without the Use of Isotopic StandardsInvestigating the complex genetic architecture of ankle-brachial index, a measure of peripheral arterial disease, in non-Hispanic whites.The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.Bakers' cyst and tibiofemoral abnormalities are more distinctive MRI features of symptomatic osteoarthritis than patellofemoral abnormalities.Biomarker discovery in MALDI-TOF serum protein profiles using discrete wavelet transformation.Resolving confusion of tongues in statistics and machine learning: a primer for biologists and bioinformaticians.The electronic nose in respiratory medicine.Systematic review and meta-analysis of the diagnostic accuracy of ductoscopy in patients with pathological nipple discharge.Improving stability of prediction models based on correlated omics data by using network approaches.Mass Spectrometry Analysis Using MALDIquant
P2860
Q30866078-9E411189-1AC6-48D9-A6AE-9EAE73F692A3Q33378995-2C64A809-7C17-4F4C-85BD-9D5B9B17AE8CQ33427635-76CAF293-3290-488A-A6FD-57C15B97E6E0Q33899074-9386272E-3DEB-455C-A624-D37A054E90D4Q34327104-2478D47E-8C85-46BD-84F6-612AA2910D27Q34395996-C38D029A-138F-4034-9064-C70D3AF41B02Q34607497-533104EB-8CE8-4149-94B1-531547D3C90BQ35266857-C1E24C51-57E7-4E4C-98FC-15FC9A42697BQ36042474-8D3A797D-52E4-440C-8F4D-69AC4C55BD1BQ36120904-AD390DE3-3ED2-4DC4-A7F9-6DC6D603F3ACQ36170999-435EF2A2-65F6-4E00-BCE6-6EA081C7F8A6Q36699490-D8F1393F-893A-4CC2-A2CF-AC8ADDB1185DQ36897732-78D475C1-8EFE-4712-9E9D-477CCD4A9F03Q36933275-02098B46-B746-4460-8197-B4A5F324C0C7Q37109837-A2DDAE85-5120-4C0A-AC02-A4D34BFE9430Q37975974-E08AC57E-C545-41A9-B55C-B029FCED26C0Q38047175-27BD65AB-C761-4F1F-A65E-1004FF24848EQ38785313-7B6AB8AA-090A-4EE5-9219-690573BF25FFQ50422497-7F28A93E-6377-4F46-8FF9-1672BD4AC00EQ57566291-083583DE-5E18-4ED7-B52F-F02B170949EF
P2860
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@ast
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@en
type
label
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@ast
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@en
prefLabel
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@ast
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@en
P2093
P356
P1476
Mass spectrometry proteomic diagnosis: enacting the double cross-validatory paradigm.
@en
P2093
A M Deelder
Bart J A Mertens
M E De Noo
R A E M Tollenaar
P304
P356
10.1089/CMB.2006.13.1591
P577
2006-11-01T00:00:00Z